Octreotide has an important role in the medical management of acromegaly. Its place in the management of acromegaly as an adjuvant therapy after neurosurgery is well established with a well-demonstrated efficacy. It can also be used in certain clinical conditions as a neoadjuvant treatment. Clinicians and patients should be aware of the possible side effects of octreotide treatment.
1
Two studies has suggested that the prevalence of acromegaly may be more widespread than previously estimated. In a study including 71,972 subjects, the prevalence of pituitary adenoma was more than 3.5-5 times than previously reported, whereas in an another study the prevalence of biochemical acromegaly by screening for elevated IGF-1 levels was even higher with 1,043 cases per million of subjects. 2, 3 The mean age at diagnosis is around 40 years. The clinical manifestations of acromegaly are varied and comprise enlargement of the extremities, soft tissue swelling, coarsening of facial features, prognathism, macroglossia, increase in ring and/or shoe size, arthritis, hyperhidrosis, and diabetes mellitus.
Acromegaly Diagnosis Criteria
The current international consensus for the diagnosis of acromegaly is based on the inability to suppress serum Gh to less than 1 μg/l after glucose administration (75 g is recommended), in conjunction with a clinical suspicion and high IGF-1 levels. 4 The diagnosis is often preceded by around 10 years of active unrecognized disease. 5 The clinical manifestations of acromegaly depend on the level of Gh and IGF-1, tumor size, the age of the patient, and the delay in diagnosis.
Treatment Options in Acromegaly
The aims of therapy in acromegaly are alleviation of symptoms, complete tumor removal, and a decrease in morbidity and mortality. 6 Complications linked to acromegaly are principally premature atherosclerosis, hypertrophic cardiomyopathy, diabetes mellitus, arthritis, sleep apnea syndrome, and polyps of the colon. 7 The cause of death in acromegaly patients is cardiovascular disease in 60 % of patients, 25 % respiratory disease, and 15 % neoplasia.
8
A biochemical complete control is achieved by a serum Gh level <1 μg/l with a sensitive immunoassay or <2.5 μg/l with a sensitive enzyme-based immunoassay, normalization of serum IGF-1 levels compared with age-and sex-matched controls, and/or Gh level under 0.4 μg/l after an oral glucose tolerance test (OGTT). 4 Management of a patient with acromegaly requires a multidisciplinary collaboration with a general practitioner, endocrinologist, neurosurgeon, and radiotherapist.
Primary surgical removal of the tumor is considered as the preferred treatment for acromegaly according to the guidelines of the American Association of Clinical Endocrinologists. 4 Transsphenoidal surgery in particular is considered as the first approach in patients with microadenomas and in patients with macroadenomas that are associated with a mass effect. Surgical excision achieves a normalization of serum IGF-1 in 56-68 % patients with noninvasive macroadenomas and in 75-95 % patients with microadenomas.
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Medical treatment is considered an adjuvant therapy in patients experiencing residual disease after surgical removal of the tumor. There are several forms of octreotide available for medical therapies that are listed in Table 1 . 
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In the recent ACrOSTuDy, which included 1,288 patients in real-life clinical practice, 88 % of patients received once per day pegvisomant alone, while 36 % were administered daily pegvisomant with another treatment. The results showed a biochemical control in 63 % patients after 5 years. 20 Two smaller studies showed a better biochemical response ranging from 84 % to 88 % in patients receiving a more optimal dose titration. 21, 22 Combination therapy including octreotide and one of the other of treatments seems to be a valuable therapeutic option in some cases. Several studies have evaluated the different combination options. Concerning the addition of dopamine agonists to SSAs a meta-analysis including 15 studies
showed that adding dopamine in previously uncontrolled patients permit a normalization of IGF-1 in 50 % patients. 23 Addition of pegvisomant in patients on octreotide therapy for those with uncontrolled acromegaly leads to a normalization of IGF-1 in about 95 % of patients.
23,24

Mechanisms of Action of SSAs
The use of long-acting release (lAr) octreotide for treatment of acromegaly is supported by more than 20 years of experience and clinical research. 25 This synthetic somatostatin binds to somatotstatin-receptor subtypes 2, 3, and 5 and inhibits the release of 5-hydroxytryptamine (5-hT) and the secretion of IGF-1, insulin, glucagon, secretin, gastrin, pancreatic polypeptide (PP), vasoactive intestinal peptide (VIP) growth hormone, and motilin. 26 Octreotide acts through four mechanisms to decrease abnormal Gh secretion in acromegaly. First, octreotide suppresses Gh secretion from the pituitary gland and from Gh-secreting adenomas. Second, it decreases Gh binding to hepatocytes. Third, it inhibits hepatic IFG-1 production and finally it controls tumor growth.
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SSAs Form and Schema of Administration
The 
Efficacy of SSAs
The efficacy of octreotide treatment as a primary treatment among different studies has shown that it achieves biochemical remission in a substantial number of patients. [34] [35] [36] The rate of biochemical response varies from 34 % to 60 %. The rate of significant tumor shrinkage (>20 %) was estimated in about 75 % of patients included in a prospective study. 34 An important The results showed that the biochemical efficacy of lAr octreotide is greater than that of lanreotide Sr among patients unselected for prior SSA responsiveness. however, there are some limitations in the results of this meta-analysis because the biochemical criteria for acromegaly remission were heterogeneous among the studies. 43 When comparing the efficacy of lAr octreotide versus lanreotide ATG there was no significant difference in biochemical control or in tumor shrinkage. 44, 45 lanreotide has the advantage of a prolonged injection interval in 50 % of patients. Another study with nine patients receiving pasireotide during 24 months showed a biochemical control of 33.3 %. 47, 48 This molecule may be more effective than lanreotide and octreotide for biochemical control and can be considered as in interesting future treatment with potential advantages SSA = somatostatin analog.
over currently used Srls. The chimeric molecule dopastatin was used in phase II trials and had poor results causing its development to be stopped.
Side Effects of SSAs
SSA therapy is generally well tolerated in most patients and treatment discontinuation related to adverse effects (AEs) is mainly due to transient gastrointestinal symptoms. [49] [50] [51] (see Table 2 Erythema, injection-site discomfort, and burning sensations are also frequently reported by patients under SSA treatment. These side effects can be avoided by warming the drug to room temperature before injection (storage of octreotide is required in a refrigerator). The formation of painful subcutaneous nodules following repeated administration of lanreotide ATG has been described. 53 SSAs can also reduce gastrin secretion with a direct inhibitory effect on the secretion of intrinsic factor increasing the risk for chronic gastritis and pernicious anemia. Surveillance should be carried out for pernicious anemia and a B12 injection should be considered in such patients.
Concerning the potential effects on glucose homeostasis, octreotide influences remain difficult to predict. Indeed, octreotide may induce both inhibition of insulin secretion, but also improve insulin sensibility by inhibiting Gh that itself cause insulin resistance.
A meta-analyisis of 619 patients treated with octreotide showed no effects on hb1Ac or fasting glucose levels, but showed a worsening response to OGTT. 54 It could be considered that ocreotide can induce diabetes mellitus and patients treated with this therapy with previous diabetes may encounter reduced or increased insulin requirements and thus a regular control of blood glucose is recommended when SSA treatment is started.
On the contrary, patients may also experience episodes of hypoglycemia because of the inhibition of glucagon secretion. hypothyroidism is another possible complication caused by octreotide because of the possible suppression of thyroid-stimulating hormone.
Others side effects that must be explained to patients are hair loss and bradycardia. Diffuse alopecia remains a rare complication of octreotide therapy that occurs less frequently with the slow-release preparation and is fully reversible after discontinuation.
Clinicians should also be aware of possible kidney injury induced by octreotide as a case of acute kidney failure caused by octreotide therapy for acromegaly has been reported. 55 Concerning pregnancy, data about octreotide use remain scarce as treatment was discontinued in most cases during pregnancy. There are, [56] [57] [58] In the absence of consistent data about octreotide, clinicians should weigh out the potential risks against the possible benefits of octreotide treatment during pregnancy.
Finally, no tachyphlylaxia has been reported during long-term therapy for patients taking octreotide for acromegaly; however, a tachyphylaxia was observed in a patient taking octreotide for a neuroendocrine gastrointestinal tumor.
Conclusion
SSAs are considered a mainstay in acromegaly therapy. Its efficacy is clearly demonstrated by numerous studies. however, clinicians and patients should be aware of the possible AEs, which can often be easily controlled and rarely require the discontinuation of treatment. n
